Citation only
via OpenAlex
Current Pharmacotherapy for Alzheimer's Disease
Alberto Lleó, Steven Mark Greenberg, John H. Growdon
Annual Review of Medicine · 2005 · ▲ 345 citations
Abstract
Alzheimer's disease (AD) is an age-related neurodegenerative disease that affects approximately 4.5 million people in the United States. The mainstays of current pharmacotherapy for AD are compounds aimed at increasing the levels of acetylcholine in the brain, thereby facilitating cholinergic neurotransmission through inhibition of the cholinesterases. These drugs, known as acetylcholinesterase inhibitors (AChEIs), were first approved by the U.S. Food and Drug Administration (FDA) in 1995 based on clinical trials showing modest symptomatic benefit on cognitive, behavioral, and global measures. In 2004 the FDA approved memantine, an NMDA antagonist, for treating dementia symptoms in moderate to severe AD cases. In clinical practice, memantine may be co-administered with an AChEI, although neither drug individually or in combination affects the underlying pathophysiology of dementia. Dementia in AD results from progressive synaptic loss and neuronal death. As knowledge of the mechanisms responsible for neurodegeneration in AD increases, it is anticipated that neuroprotective drugs to slow or prevent neuronal dysfunction and death will be developed to complement current symptomatic treatments.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1146/annurev.med.57.121304.131442
- Canonical
- link ↗
- Fetched
- 2026-10-16 MST
Cite this
APA
Lleó, A., Greenberg, S.M., & Growdon, J.H. (2005). Current Pharmacotherapy for Alzheimer's Disease. <em>Annual Review of Medicine</em>. https://doi.org/10.1146/annurev.med.57.121304.131442
Vancouver
Lleó A, Greenberg SM, Growdon JH. Current Pharmacotherapy for Alzheimer's Disease. Annual Review of Medicine. 2005. doi:10.1146/annurev.med.57.121304.131442.
BibTeX
@article{alberto2005Curren,
title = {Current Pharmacotherapy for Alzheimer's Disease},
author = {Alberto Lleó and Steven Mark Greenberg and John H. Growdon},
journal = {Annual Review of Medicine},
year = {2005},
doi = {10.1146/annurev.med.57.121304.131442},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Human Molecular Genetics 2007
Open access · OA
Parkinson's disease
Aging and Disease 2016
Open access · CC-BY
Mitochondrial Dysfunction in Alzheimer’s Disease and the Rationale for Bioenergetics Based Therapies
Mechanisms of Ageing and Development 2016
Open access · CC-BY
The chicken or the egg: mitochondrial dysfunction as a cause or consequence of toxicity in Huntington’s disease
Frontiers in Neuroscience 2018
Open access · CC-BY
Mitochondria and Calcium Regulation as Basis of Neurodegeneration Associated With Aging
Cells 2026
Open access · OA
Mitochondrial Dysfunction in Alzheimer's Disease and Mitochondria-Targeted Therapeutics.
Current Issues in Molecular Biology 2024
Open access · CC-BY